Your shopping cart is currently empty

MC180295 ((rel)-MC180295) is a novel, potent, and highly selective CDK9 inhibitor with an IC50 of 5 nM, demonstrating over 22-fold selectivity compared to other CDKs.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $51 | In Stock | In Stock | |
| 5 mg | $133 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $335 | In Stock | In Stock | |
| 50 mg | $472 | In Stock | In Stock | |
| 100 mg | $672 | In Stock | In Stock | |
| 200 mg | $886 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $146 | In Stock | In Stock |
| Description | MC180295 ((rel)-MC180295) is a novel, potent, and highly selective CDK9 inhibitor with an IC50 of 5 nM, demonstrating over 22-fold selectivity compared to other CDKs. |
| Targets&IC50 | CDK9-CyclinT1:5 nM (cell free), CDK1-CyclinB:138 nM (cell free), CDK7-CyclinH-MAT1:555 nM, CDK5-p35:159 nM (cell free), CDK6-CyclinD1:712 nM, CDK4-CyclinD:112 nM (cell free), CDK5-p25:186 nM (cell free), CDK2-CyclinE:367 nM, CDK2-CyclinA:233 nM, CDK3-CyclinE:399 nM |
| In vitro | MC180295 is a potent, selective CDK9-Cyclin T1 inhibitor with an IC50 of 5 nM, displaying at least 22-fold selectivity over other CDKs, including CDK1-Cyclin B (IC50, 138 nM), CDK2-Cyclin A (IC50, 233 nM), CDK2-Cyclin E (IC50, 367 nM), CDK3-Cyclin E (IC50, 399 nM), CDK4-Cyclin D (IC50, 112 nM), CDK5-P35 (IC50, 159 nM), and CDK5-P25 (IC50, 186 nM). MC180295 (0.1 μM) demonstrates broad anti-cancer activity in vitro. |
| In vivo | MC180295 (20 mg/kg, i.p., qod) demonstrates significant anti-tumor activity in mice with SW48 cells without inhibiting human T cell growth in vivo. |
| Synonyms | (rel)-MC180295 |
| Molecular Weight | 358.41 |
| Formula | C17H18N4O3S |
| Cas No. | 2237942-08-2 |
| Smiles | Nc1nc(N[C@H]2C[C@@H]3CC[C@H]2C3)sc1C(=O)c1ccccc1[N+]([O-])=O |
| Relative Density. | 1.462 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (418.52 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.